Request Demo
Last update 09 May 2025
BL-1021
Last update 09 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms AN-228, BL 1021 |
Target |
Action blockers |
Mechanism Nav1.6 blockers(Sodium channel protein type VIII alpha subunit blockers), Nav1.7 blockers(Sodium channel protein type IX alpha subunit blockers), Nav1.8 blockers(Sodium channel protein type X alpha subunit blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC23H29ClN2O |
InChIKeyDEKZAWRGNGHZKY-UHFFFAOYSA-N |
CAS Registry1002331-76-1 |
Related
1
Clinical Trials associated with BL-1021NCT01121380
A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single-Center Combined Single-Ascending Dose and Multiple-Ascending Dose, Parallel Groups, Study to Assess Safety, Tolerability and Pharmacokinetics of BL-1021 in Healthy Volunteers
100 Clinical Results associated with BL-1021
Login to view more data
100 Translational Medicine associated with BL-1021
Login to view more data
100 Patents (Medical) associated with BL-1021
Login to view more data
1
Literatures (Medical) associated with BL-102114 May 2009Journal of medicinal chemistryQ1 · MEDICINE
γ-Aminobutyric Acid Amides of Nortriptyline and Fluoxetine Display Improved Pain Suppressing Activity
Q1 · MEDICINE
Article
Author: Gil-Ad, Irit ; Nudelman, Abraham ; Tarasenko, Igor ; Geffen, Yona ; Weizman, Abraham ; Rephaeli, Ada ; Aharoni, Ana ; Halbfinger, Efrat ; Nisemblat, Yotam ; Tarasenko, Nataly
The GABA amides of the antidepressants nortriptyline and fluoxetine, 1 and 2, were compared to their respective parent compounds in rodent models of pain. The amides significantly reduced early nociceptive and late inflammatory responses compared to nortriptyline or fluoxetine, where 1 exhibited overall better efficacy than 2. Amide 1 was most efficacious in lowering cytokine secretion, edema and hyperalgesia induced by formalin and lambda-carrageenan, respectively. Thus, 1 is a promising candidate for the treatment of pain.
100 Deals associated with BL-1021
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neuralgia | Phase 1 | - | - | |
| Neuralgia | Phase 1 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free